Washington, D.C. partners Ben Haas and Elizabeth Richards discuss the FDA’s efforts to modernize the regulatory pathway to marketing to account for artificial intelligence and machine learning in devices. In addition, they look at how FDA is viewing real world evidence and how it may be utilized for regulatory purposes.